Inita Buliņa

Medicine & Life Sciences

1. Rheumatic Diseases 100%
2. Rheumatology 70%
3. Latvia 54%
4. Antirheumatic Agents 42%
5. Registries 40%
6. Musculoskeletal Diseases 32%
7. Vaccination 30%
8. SARS Virus 28%
9. Pandemics 28%
10. Vaccines 21%
11. Hospitalization 18%
12. Ankylosing Spondylitis 18%
13. Physicians 16%
14. Tumor Necrosis Factor Inhibitors 15%
15. Comorbidity 14%
16. Janus Kinase Inhibitors 14%
17. Polymyalgia Rheumatica 13%
18. Rheumatologists 12%
19. Rheumatoid Arthritis 12%
20. Juvenile Arthritis 11%
21. Hemophagocytic Lymphohistiocytosis 11%
22. Systemic Vasculitis 11%
23. Coronavirus 11%
24. Fatigue 11%
25. Rare Diseases 10%
26. Connective Tissue Diseases 10%
27. Systemic Scleroderma 10%
28. Ireland 10%
29. Systemic Lupus Erythematosus 9%
30. Rituximab 9%
31. Autoimmune Diseases 9%
32. Ambulatory Care 8%
33. Outpatients 8%
34. Glucocorticoids 8%
35. Mortality 8%
36. Obstetrics 7%
37. Disease Progression 7%
38. Abatacept 7%
39. Observational Studies 7%
40. Cohort Studies 7%
41. Eye Manifestations 6%
42. Arthritis 6%
43. Delivery of Health Care 6%
44. Body Mass Index 6%
45. Retrospective Studies 6%
46. Infections 6%
47. Baths 5%
48. Methotrexate 5%
49. Safety 5%
50. Non-Steroidal Anti-Inflammatory Agents 5%